NAGE Q3 2019 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$393M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+48.4% YoY

Gross Profit

$7M56.0% margin

Operating Income

-$7M-57.1% margin

Net Income

-$7M-59.8% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+8.6%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$43M

Total Liabilities

$16M

Stockholders' Equity

$27M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$8M	+48.4%
Gross Profit	$7M	$4M	+54.8%
Operating Income	-$7M	-$9M	+19.9%
Net Income	-$7M	-$9M	+16.3%